Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

BACKGROUND: Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized clinical trials (2 episodic trials [EVOLVE-1, EVOLVE-2] and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ament, Michael, Day, Kathleen, Stauffer, Virginia L, Skljarevski, Vladimir, Rettiganti, Mallikarjuna, Pearlman, Eric, Aurora, Sheena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868011/
https://www.ncbi.nlm.nih.gov/pubmed/33549036
http://dx.doi.org/10.1186/s10194-021-01215-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868011/
https://www.ncbi.nlm.nih.gov/pubmed/33549036
http://dx.doi.org/10.1186/s10194-021-01215-9

Ejemplares similares